Xlife Sciences AG/ CH0461929603 /
| - - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| -EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 171.03 mill.EUR | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 2.73 CHF | 0.37% |
| EPS Diluted: | - CHF | 4.00% |
| Revenues per Share: | 0.18 CHF | -9.15% |
| Book Value per Share: | 47.95 CHF | 7.71% |
| Cash Flow per Share: | 0.03 CHF | - |
| Dividend per Share: | - CHF | - |
| Total | in mill. | |
| Revenues: | 0.99 CHF | -3.85% |
| Net Income: | 14.88 CHF | 3.96% |
| Operating Cash Flow: | 0.17 CHF | - |
| Cash and Cash Equivalents: | 0.22 CHF | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 10.48 | 18.28 |
| P/S Ratio: | 161.81 | 282.32 |
| P/BV ratio: | 0.60 | 1.04 |
| P/CF Ratio: | 931.05 | 1,624.46 |
| PEG: | 28.50 | 49.72 |
| Earnings Yield: | 9.55% | 5.47% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 171.03 mill. EUR | 300.47 mill. EUR |
| Free Float Market Cap.: | - EUR | - EUR |
| Market Cap. / Employee: | - EUR | - EUR |
| Shares Outstanding: | 5.59 mill. | |
Profitability
| Gross Profit Margin: | 45.43% |
| EBIT Margin: | -2,054.56% |
| Net Profit Margin: | 1,505.34% |
| Return on Equity: | 5.55% |
| Return on Assets: | 2.91% |
Financial Strength
| Liquidity I / Cash Ratio: | 3.75% |
| Liquidity II / Quick Ratio: | 160.25% |
| Liquidity III / Current Ratio: | 310.67% |
| Debt / Equity Ratio: | 90.92% |
| Dynam. Debt / Equity Ratio: | 141,934.48% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - CHF |
| Revenues / Employee: | - CHF |
| Net Income / Employee: | - CHF |
| Total Assets / Employee: | - CHF |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | IFRS |
| Currency: | CHF |
